Merck's Keytruda shows overall survival benefit in ovarian cancer
Source: SeekingAlpha
2026-02-27 11:38:24 ET
More on Merck
- Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie
- Merck: Why Investors Should Remain Bullish Despite Patent Risks
- Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction
- FDA reportedly eyeing staff bonuses to accelerate drug reviews
- 15 states sue Trump administration over changes to U.S. vaccine schedule
Read the full article on Seeking Alpha
For further details see:
Merck's Keytruda shows overall survival benefit in ovarian cancer
Astellas Pharma Inc. ADR
NASDAQ: ALPMY
ALPMY Trading
-0.89% G/L:
$14.75 Last:
104,314 Volume:
$15.43 Open:
ALPMY Latest News
January 08, 2026 10:30:00 am
VYLOY(TM) (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses
December 17, 2025 06:45:00 am
PADCEV(TM) Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
December 10, 2025 06:30:00 pm
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
ALPMY Stock Data
$29,447,472,947
1,772,218,737
N/A
5
N/A
Pharmaceuticals
Healthcare
JP
Chuo-Ku
